Key points from article :
Fountain Therapeutics announced closing of $6 million Series A-1 financing.
This brings its total Series A funding to $11 million.
The round was led by Khosla Ventures, with participation from Nan Fung Life Sciences.
Now financially capable to rapidly discover and develop a pipeline of novel therapeutics.
Through preclinical testing in animal models, to target, reverse biological process of ageing.
With the potential to improve the quality of life for our ageing population.
Proceeds will also be used to expand the senior leadership team.
